Strategic Cooperation Agreement With Fonow Medicine In Relation To KT-939
Release time：2026-03-12 21:52
Suzhou, 12 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( “ Suzhou Kintor ”), a wholly-owned subsidiary of the Company, entered into the strategic cooperation agreement (the “ Cooperation Agreement ”) with Zhejiang Fonow Medicine Co., Ltd. *(浙江孚诺医药股份有限公司 ) (“ Fonow Medicine ”) in relation to jointly development of whitening and freckle-removing functional cosmetics containing the Company’s innovative raw material KT-939 as an adjunct option for reducing and improving skin pigmentation.
Pursuant to the Cooperation Agreement, the Suzhou Kintor will provide the Fonow Medicine with KT-939 raw material, and grant it the right to develop, manufacture, and sale whitening and freckle-removing products with KT-939 as the main active ingredient in mainland China, to be used as an adjunct to Folimei® Cream, one of its core products, for melasma treatment. Both parties will engage in in-depth cooperation in technological refinement and end-product development to advance the R&D, registration, and manufacturing of the functional special cosmetics containing KT-939 raw material, with Fonow Medicine responsible for the subsequent commercialization.
Fonow Medicine , founded in 2002, is a national high-tech enterprise specializing in R&D, manufacture, and sales of topical dermatological drugs , with a commitment of becoming a leading player in the R&D and manufacture of dermatological drugs in China . Fonow Medicine operates three R&D and manufacturing bases, covering a total area of 180 acres, and has a full dosage form production platform for topical skin preparations. It has obtained GMP certification and ISO9001/14001/45001 international standard certifications.
With over two decades of deep cultivation in topical dermatological drugs field, Fonow Medicine has established three key technology platforms: topical skin preparations R&D, active pharmaceutical ingredient development, and the research of biologically active substance used in pharmaceutical product. Leveraging these platforms, it has developed flagship products with significant clinical value, including Fonow® Ointment and Folimei® Cream. Fonow® Ointment is the first-to-market generic and exclusive product in China, primarily indicated for promoting wound healing, with annual sales exceeding 10 million units. In particular, its consistent therapeutic efficacy and strong market recognition have enabled it to rank first in sales of topical antibiotics for nine consecutive years in the China public hospital market. Folimei® Cream is a new-generation topical drug for melasma treatment as the first-to-market generic product in China. It offers the dual effect of depigmenting and anti-irritation, effectively improving hyperpigmentation while minimizing skin sensitivity. As a result, it has become the standard medication of first-line treatment for melasma as the first drug in China.
The signing of the Cooperation Agreement with Fonow Medicine is aimed at establishing a long-term and stable strategic cooperation, thereby fully leveraging the complementary strengths to each other in innovative raw material R&D and topical product development to drive the commercialization and market expansion of KT-939, a functional cosmetic ingredient. Through this collaboration, Suzhou Kintor will further accelerate the commercialization process of KT-939, broaden its market coverage and influence, and translate its technological advantages into market value, providing ancillary support to first-line treatment for the broad population of melasma patients.
recommend News
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn